Targets › PDE6A
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jul 2027.
Catalytic alpha subunit of the rod-specific cGMP phosphodiesterase (PDE6) complex, which hydrolyzes 3',5'-cyclic GMP in the phototransduction cascade. The PDE6 holoenzyme consists of two catalytic subunits (PDE6A and PDE6B) and two inhibitory gamma subunits (PDE6G). (UniProt, P16499)
Open in Phaseline: the race on PDE6A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| STZ eyetrial | rAAV.hPDE6A Recombinant adeno-associated viral vector delivering human PDE6A gene to restore rod phosp | PDE6A | Phase 1 | Retinitis Pigmentosa | Jul 2027 |
Retinitis Pigmentosa (1)
other (1)
STZ eyetrial (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.